Literature DB >> 15001326

Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies.

Jeremy G Wheeler1, Bernard D Keavney, Hugh Watkins, Rory Collins, John Danesh.   

Abstract

BACKGROUND: Although there have been suggestions that serum paraoxonase is important in protecting against coronary heart disease (CHD), a large number of studies of genetic determinants of serum paraoxonase have reported apparently conflicting results about their association with CHD.
METHODS: We conducted a meta-analysis of 43 studies of the Q192R, L55M, and T(-107)C polymorphisms in the paraoxonase PON1 gene and the S311C polymorphism in the PON2 gene (all of which are in moderately strong linkage disequilibrium with one another), involving a total of 11212 CHD cases and 12786 controls. We explored potential sources of heterogeneity.
FINDINGS: In a combined analysis of all studies, the per-allele relative risk of R192 for CHD was 1.12 (95% CI 1.07-1.16), but in the five largest studies it was only 1.05 (0.98-1.13). Combined analyses of studies of the M55, (-107)T, and C311 variants showed no significant overall associations with CHD, yielding per-allele relative risks of 1.00 (0.95-1.06), 1.02 (0.92-1.14), and 1.04 (0.93-1.17), respectively.
INTERPRETATION: In contrast to previous suggestions, this meta-analysis shows no significant association of CHD with the L55M or T(-107)C polymorphism in PON1 or with the S311C polymorphism in PON2. The weak overall association between the Q192R polymorphism and CHD is of uncertain relevance, particularly since there was no significant association among the larger studies which should be less prone to selective publication. These findings reinforce the need for much larger and more rigorous investigations of the genetic determinants of complex diseases than is now customary, as well as for regularly updated systematic appraisals of such studies to help improve interpretation and prioritise hypotheses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001326     DOI: 10.1016/S0140-6736(04)15642-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  88 in total

1.  Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis.

Authors:  Indranil Banerjee
Journal:  Eur J Epidemiol       Date:  2010-06-09       Impact factor: 8.082

2.  Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease.

Authors:  Porat M Erlich; Kathryn L Lunetta; L Adrienne Cupples; Carmela R Abraham; Robert C Green; Clinton T Baldwin; Lindsay A Farrer
Journal:  Neurobiol Aging       Date:  2010-10-27       Impact factor: 4.673

3.  Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis.

Authors:  Luis M Moura; Susana Faria; Miguel Brito; Fausto J Pinto; Steen D Kristensen; Isabel M Barros; Nalini Rajamannan; Francisco Rocha-Gonçalves
Journal:  Am J Cardiovasc Dis       Date:  2012-05-15

Review 4.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 5.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

Review 6.  The roles of PON1 and PON2 in cardiovascular disease and innate immunity.

Authors:  Diana M Shih; Aldons J Lusis
Journal:  Curr Opin Lipidol       Date:  2009-08       Impact factor: 4.776

Review 7.  The paraoxonase gene family and atherosclerosis.

Authors:  David Seo; Pascal Goldschmidt-Clermont
Journal:  Curr Atheroscler Rep       Date:  2009-05       Impact factor: 5.113

8.  Paraoxonase 1 (PON1) status and substrate hydrolysis.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-13       Impact factor: 4.219

9.  Paraoxonase 1 L55M, Q192R and paraoxonase 2 S311C alleles in atherothrombosis.

Authors:  L Cozzi; J Campolo; M Parolini; R De Maria; M C Patrosso; A Marocchi; O Parodi; S Penco
Journal:  Mol Cell Biochem       Date:  2012-12-06       Impact factor: 3.396

10.  Paraoxonase 1 polymorphisms and risk of myocardial infarction in women and men.

Authors:  Kenneth J Mukamal; Jennifer K Pai; Majken K Jensen; Eric B Rimm
Journal:  Circ J       Date:  2009-05-15       Impact factor: 2.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.